|
Gene-environment Interaction In Yeast Gene Expression (Science Daily)
Researchers have shown that gene-environment interaction is a common phenomenon in the regulation of gene expression. In a new study, they describe how different classes of genetic variants affect the nature of the interactions, and provide detailed molecular examples of interactions.
(Apr 14, 2008)
Roswell Park's Norma Nowak, PhD, Part of the Award Winning Team (Newswise)
Norma J. Nowak, PhD, a nationally recognized leader in genomic technology and cancer genetics research at Roswell Park Cancer Institute (RPCI), joined colleagues from the University of California, San Francisco, Comprehensive Cancer Center and Lawrence Berkeley National Laboratory in accepting the AACR Team Science Award at the 2008 annual meeting of the American Association for Cancer Research ...
(Apr 14, 2008)
Power3 Medical Products Receives CLIA Compliance Recertification (Centre Daily Times)
Power3 Medical Products, Inc. (OTCBB: PWRM, https://www.power3medical.com) a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, has received its CLIA compliance recertification following a CLIA regulatory inspection.
(Apr 14, 2008)
Method To Deliver Molecules Within Embryonic Stem Cells Improves Differentiation (Science Daily)
New research shows that delivering molecules within aggregates of embryonic stem cells via biodegradable microspheres enhances the efficiency and purity of differentiation.
(Apr 14, 2008)
Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab To Develop And Validate Tests Applying Company's ... (BioresearchOnline)
Rosetta Genomics, Ltd., a leader in the development of microRNA-based diagnostic and therapeutic products, announced it has signed an agreement with University of California, Irvine School of Medicine (UC Irvine), relating to the development and validation of diagnostic tests based on the company's microRNA technology
(Apr 14, 2008)
SeqWright Expands Next Generation Lineup With The Addition Of 454's GS FLX System (BioresearchOnline)
SeqWright Inc., a leading Genomics CRO, has added 454's GS FLX system to increase the breadth of its next generation offerings and to provide genomic researchers with more cost effective genomics solutions
(Apr 14, 2008)
UC Irvine to Validate MicroRNA Dx Tests for Rosetta Genomics (GenomeWeb News)
GenomeWeb Daily News You are not logged in. Existing subscribers login here . New to GenomeWeb Daily News? Register quickly here for your free subscription.
(Apr 14, 2008)
(AFX UK Focus) 2008-04-14 16:05 GMT: TFN NEWS BRIEFING: Mergers and acquisitions highlights to 15:50 BST (Interactive Investor)
2008-04-14 15:37:49 Blockbuster offers to buy Circuit City
(Apr 14, 2008)
Keynote Panel at Bio-IT World Expo to Feature Six Leaders in the Field of "Personal Genomics" (Marketwire via Yahoo! Finance)
A plenary panel discussion on the exciting field of "personal genomics," featuring six of the most outstanding scientists, physicians and commentators in the field, is among the highlights of the 2008 Bio-IT World Conference & Expo being held April 28 - 30 at the World Trade Center in Boston.
(Apr 14, 2008)
febit First to Offer miRBase 11.0 Biochip (PR Newswire via Yahoo! Finance)
febit today announced its newest miRNA Biochip based on the new miRBASE version 11.0 which has been released by the Wellcome Trust Sanger Institute yesterday. The new Geniom® Biochip opens up the most up-to-date scientific information for miRNA microarray experiments.
(Apr 14, 2008)
Genome scans go deep into your DNA (Los Angeles Times)
Dad's cholesterol? Grandma's hypertension? Extensive genetic scans can tell us who we really are inside. However, there is such a thing as TMI. MY MATERNAL grandmother had Alzheimer's disease. Before she died, she forgot our names, our faces and, eventually, how to speak and think. But my grandfather's heartbreak was the most painful to witness. I remember watching the two of them on the sofa ...
(Apr 14, 2008)
Tomato pathogen genome may offer clues about bacterial evolution (PhysOrg)
The availability of new genome sequencing technology has prompted a Virginia Tech plant scientist to test an intriguing hypothesis about how agriculture`s early beginnings may have impacted the evolution of plant pathogens.
(Apr 14, 2008)
Blood urate levels associated with the progression of Parkinson's disease (EurekAlert!)
Higher blood levels of the compound urate, a salt derived from uric acid that is associated with gout, may be associated with a slower progression of Parkinson's disease, according to an article posted online today that will appear in the June 2008 print issue of Archives of Neurology, one of the JAMA/Archives journals.
(Apr 14, 2008)
Affymetrix Announces Preliminary First Quarter Revenue (Centre Daily Times)
Affymetrix, Inc. (Nasdaq:AFFX), today reported that based on preliminary financial data, the Company expects total revenue for the first quarter of 2008 to be approximately $170 million, including an intellectual property payment of $90 million received by the Company in connection with a previously announced settlement of patent litigation.
(Apr 14, 2008)
Buck Institute and Q Therapeutics Form Stem Cell Collaboration to Combat Parkinson's Disease (Centre Daily Times)
The Buck Institute for Age Research and Q Therapeutics, Inc. announced today an agreement to collaborate on novel routes to combat Parkinson's disease.
(Apr 14, 2008)
AVEO Pharmaceuticals' Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal ... (Centre Daily Times)
AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that their novel oral triple VEGF receptor inhibitor AV-951 shows clinical activity in multiple advanced solid tumor types including renal, colon and lung cancers and is well tolerated according to new data ...
(Apr 14, 2008)
AVEO Pharmaceuticals´ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal ... (wallstreet:online AG)
AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer
(Apr 14, 2008)
ChemGenex Reports Oral Bioavailability of Omacetaxine and Expands on Mechanism of Action (Business Wire via Yahoo!7 Finance)
ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that pre-clinical data characterizing the bioavailability and mechanism of action of omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) were presented on Monday local time at the American Association of Cancer Research (AACR) 99th Annual Meeting in San Diego, California.
(Apr 14, 2008)
TRADE NEWS: Agilent's Stratagene Announces Expanded Line of QPCR, QRT-PCR Reagents at American Association for Cancer ... (Business Wire via Yahoo! Finance)
SAN DIEGO----Stratagene, an Agilent Technologies Inc. company, announced today it has launched an expanded line of quantitative PCR reagents with enhanced sensitivity of detection. This new line of Brilliant II QPCR and QRT-PCR reagents was developed specifically to provide improved performance on the Stratagene Mx systems.
(Apr 14, 2008)
New insights into the genetic basis of resistance to chemotherapy in children with acute leukemia (EurekAlert!)
In a new study published in PLoS Medicine, William Evans of St Jude Children’s Research Hospital, Memphis, and colleagues provide new insight into resistance to the widely-used cancer drug methotrexate (MTX) in patients with acute lymphoblastic leukaemia (ALL), the most common cancer in children.
(Apr 15, 2008)
TRADE NEWS: Agilent's Stratagene Announces Expanded Line of QPCR, QRT-PCR Reagents at American Association for Cancer ... (Centre Daily Times)
Stratagene, an Agilent Technologies Inc. (NYSE:A) company, announced today it has launched an expanded line of quantitative PCR reagents with enhanced sensitivity of detection. This new line of Brilliant II QPCR and QRT-PCR reagents was developed specifically to provide improved performance on the Stratagene Mx systems. The launch of Brilliant II is the first major product introduction by ...
(Apr 15, 2008)
Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma (Science Daily)
A novel molecule, GDC-0449, shrinks tumors for patients with advanced basal cell carcinoma with limited side effects, suggesting a viable new treatment option for patients with the advanced form of this cancer. "Basal cell carcinoma affects about one million people a year, and a very small fraction of these patients have disease that is not curable with surgery. We currently do not have any ...
(Apr 15, 2008)
Lawmaker Urges Passage of Tobacco Regulation Bill (The New York Sun)
A New York lawmaker is calling on Congress to pass legislation that would further regulate how tobacco products are sold and marketed to children. Rep. Vito Fossella, a Republican of Staten Island, along with representatives from the American Cancer Society, lobbied on behalf of the legislation, which would ban the sale of cigarettes to children, restrict marketing targeting children, ban fruit- ...
(Apr 15, 2008)
San Francisco (The San Francisco Examiner)
SAN DIEGO , April 15 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC ), presented data from a preclinical study demonstrating that the Company's experimental drug candidate, brostallicin, killed colon and ovarian cancer cells regardless of their p53 status.
(Apr 15, 2008)
New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit (Medical News Today)
Systems Medicine LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), presented data from a preclinical study identifying the genetic markers in patients more likely to respond to treatment with the experimental drug, brostallicin, at the 2008 American Association for Cancer Research (AACR) annual meeting.
(Apr 15, 2008)
MWG Biotech Purchases Second Genome Sequencer FLX System to Expand Capacities in Line with Growing Sequencing Demand (Centre Daily Times)
454 Life Sciences, a centre of excellence of Roche Applied Science, today announced that MWG Biotech, a European market leader in genome sequencing services, is further expanding its 454 Sequencing capacity in order to meet the demands of a steadily increasing number of sequencing customers across Europe.
(Apr 15, 2008)
AltheaDx Named Affymetrix Authorized Service Provider (Marketwire via Yahoo! Finance)
AltheaDx, a leading provider of contract testing services to the pharmaceutical and biotechnology industry, today announced a supply and service provider agreement with Affymetrix Inc. (NASDAQ: AFFX). The agreement enables AltheaDx to offer complete biomarker discovery and development services based on the Affymetrix GeneChip® microarray platform.
(Apr 15, 2008)
Portsmouth area community calendar (Portsmouth Herald)
Portsmouth
(Apr 15, 2008)
New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma (Medical News Today)
A novel molecule, GDC-0449, shrinks tumors for patients with advanced basal cell carcinoma with limited side effects, suggesting a viable new treatment option for patients with the advanced form of this cancer, according to research presented at the 2008 Annual Meeting of the American Association for Cancer Research.
(Apr 15, 2008)
The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium (PR Newswire via Yahoo! Finance)
GeneGo, Inc., the leading systems biology tools company, announced today that The Scripps Translational Science Institute has joined the MetaMiner Cardiac Consortium. The goal of the Consortium is to build the first systems biology and pathway analysis platform for cardiovascular diseases in the world.
(Apr 15, 2008)
Calibrant Biosystems Announces Appointment of Dr. Satya Saxena as Vice-President of Research (Business Wire via Yahoo! Finance)
GAITHERSBURG, Md.----Calibrant Biosystems today announced the appointment of Dr. Satya Saxena as its Vice-President of Research. Dr. Saxena will lead Calibrant's proteomic technology and product development programs.
(Apr 15, 2008)
Biotherapy, a new wave of medicine for cancer treatment (Radio Singapore International)
The doctor’s pronouncement of cancer still strikes fear in people’s hearts like few other diseases do. And with good reason. After all, cancer is caused by the abnormal and uncontrolled division of the body’s own cells and despite unparalleled advancements in medicine, is often a death sentence.
(Apr 15, 2008)
Affymetrix Extends Collaborations in Cancer Research Program to North America (Business Wire via Yahoo! Finance)
SANTA CLARA, Calif.----Affymetrix Inc. today extended its Collaborations in Cancer Research Program to North America, forming an alliance between Affymetrix and 25 leading cancer researchers.
(Apr 15, 2008)
Calibrant Biosystems Announces Appointment of Dr. Satya Saxena as Vice-President of Research (Centre Daily Times)
Calibrant Biosystems today announced the appointment of Dr. Satya Saxena as its Vice-President of Research. Dr. Saxena will lead Calibrant's proteomic technology and product development programs. His primary focus will include expanding and validating the Gemini(TM) platform technology beyond the initial programs in oncology. He will also oversee the continuing drug development efforts involving ...
(Apr 15, 2008)
Synthetic Biology: Its Promise And The Challenge (Medical News Today)
Synthetic biology is a new area of biotechnology research that holds a great deal of promise and controversy. Using in-depth understanding of genomes, scientists are now designing and building DNA from scratch. The results are useful organisms that can efficiently produce advanced biofuels and medicines.
(Apr 15, 2008)
Early Planting Increases Soy Yields (AgWeb.com)
Getting beans in the ground earlier in the spring will benefit come harvest time, according to University of Nebraska research.
(Apr 15, 2008)
Munich, Germany (SeedQuest)
April 15, 2008. MWG Biotech , European market leader in genome sequencing and leading expert in next generation sequencing is further expanding its capacities in order to meet the demands of a steadily increasing number of sequencing customers across Europe.
(Apr 15, 2008)
2 new therapies show promise for cancer patients (EurekAlert!)
San Diego and Phoenix—April 15, 2008—Clinical researchers at Scottsdale Healthcare and TGen today announced the results of two clinical trials that show promise for patients battling cancer.
(Apr 15, 2008)
St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia (PR Newswire via Yahoo! News)
The findings provide new insights into genomic basis of methotrexate resistance and differences in methotrexate response
(Apr 15, 2008)
Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia (Newswise)
The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children's Research Hospital study.
(Apr 15, 2008)
Health disparities: genetics plays an important role in cancer detection, prognosis among minorities (EurekAlert!)
SAN DIEGO – Research reported at the 2008 Annual Meeting of the American Association for Cancer Research, April 12-16, suggests that poorer outcomes for breast cancer and prostate cancer among minorities may be due to biologic factors.
(Apr 15, 2008)
Health Disparities: Genetics Plays an Important Role in Cancer Detection, Prognosis Among Minorities (Newswise)
Research reported at the 2008 Annual Meeting of the American Association for Cancer Research, April 12-16, suggests that poorer outcomes for breast cancer and prostate cancer among minorities may be due to biologic factors. In addition, researchers present a new theory on why a recent decline in breast cancer rates was less pronounced among African-American women, and offer data on a relatively ...
(Apr 15, 2008)
On The Release of His New Book Biotech 2008, Biotech Visionary G. Steven Burrill Will Discuss the Transformation That ... (Business Wire via Yahoo! Finance)
SAN FRANCISCO----The convergence of genomics, info- and nanotechnologies will radically alter every aspect of the healthcare system from the way companies develop and market drugs to the way individuals pay for and receive medical services, according to G.
(Apr 15, 2008)
On The Release of His New Book Biotech 2008, Biotech Visionary G. Steven Burrill Will Discuss the Transformation That ... (Centre Daily Times)
The convergence of genomics, info- and nanotechnologies will radically alter every aspect of the healthcare system from the way companies develop and market drugs to the way individuals pay for and receive medical services, according to G. Steven Burrill author of Biotech 2008 --Life Sciences: A 20/20 Vision for 2020(1).
(Apr 15, 2008)
Lexicon Presents Clinical Data for LX6171, a Drug Candidate for Cognitive Disorders (PrimeNewswire via Yahoo! Finance)
THE WOODLANDS, Texas, April 15, 2008 -- Lexicon Pharmaceuticals, Inc. , a leader in genomics-based drug discovery, presented data today describing the target of LX6171 and initial Phase 1 clinical results at the American Academy of Neurology in Chicago.
(Apr 15, 2008)
CDC's Genomics Office to Grant Around $3.6M to Translate Genomics to Practice (GenomeWeb News)
GenomeWeb Daily News You are not logged in. Existing subscribers login here . New to GenomeWeb Daily News? Register quickly here for your free subscription.
(Apr 15, 2008)
Clinton Delivers Remarks at Associated Press Annual Meeting (Washington Post)
SEN. HILLARY RODHAM CLINTON, D-N.Y.: I know that in this audience there are members of the media from New York, including Margaret Sullivan from the Buffalo News and Arthur Salzberger from the New York Times and others who I don't have on this card, but I am very pleased to be here with all of yo...
(Apr 15, 2008)
Cancer-drug trials show promise (The Arizona Republic)
Two Arizona-based cancer drug trials show early favorable results.
(Apr 16, 2008)
5-year-old gene-based research institution fights for funding (The Arizona Republic)
TGen is competing for a dwindling supply of contributions to pursue its medical advancements.
(Apr 16, 2008)
Global Molecular Diagnostics Market to Reach $3.67 Billion by 2010, According to New Report by Global Industry ... (PRWeb via Yahoo! News)
World molecular diagnostics market is projected to touch $3.67 billion by 2010. Molecular diagnostics is a rapidly advancing market within the medical diagnostics market, backed by hectic activity in the biomarker research arena, and exploding new applications for these tests.
(Apr 16, 2008)
|
